Clinical Trial Update: Selumetinib and Erlotinib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating selumetinib with erlotinib in locally advanced or metastatic pancreatic cancer has completed with results posted in 2016.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Adenocarcinoma
• Pancreatic Cancer

Drugs mentioned

• Erlotinib hydrochloride (Erlotinib)
• Selumetinib (selumetinib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer | Phase 2 | Status: COMPLETED | Results posted: 2016-11-07